Ozempic vs. Zepbound

See how Ozempic and Zepbound compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Ozempic is FDA-approved for type 2 diabetes plus cardiovascular and kidney protection, while Zepbound is FDA-approved for chronic weight management and sleep apnea.

  • Both drugs cause similar gastrointestinal side effects, but Zepbound's weight-loss doses report higher rates of nausea, diarrhea, and constipation than Ozempic's diabetes doses.

  • Using Ozempic for weight loss is off-label, while Zepbound was developed and approved specifically for that purpose.

Ozempic vs. Zepbound Drug Summary

Ozempic

Ozempic (semaglutide) is a GLP-1 receptor agonist approved in 2017 to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is also approved to lower cardiovascular risk in diabetics with heart disease and to slow chronic kidney disease progression. It is given as a once-weekly subcutaneous injection.

Zepbound

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist, first approved in 2022, now indicated for chronic weight management in adults with obesity or overweight plus a related health condition. It also treats moderate-to-severe obstructive sleep apnea in adults with obesity. It is given as a once-weekly subcutaneous injection.

Ozempic vs. Zepbound Side Effects

Ozempic

Most common
Nausea (up to 20.3%)
Vomiting (up to 9.2%)
Diarrhea (up to 8.8%)
Abdominal pain (up to 7.3%)

Zepbound

Most common
Nausea (up to 29%)
Vomiting (up to 13%)
Diarrhea (up to 23%)
Constipation (up to 17%)

Ozempic vs. Zepbound Dosage

Ozempic

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2 mg once weekly If needed
Dose changes 3 increases Every 4 weeks

Zepbound

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly If needed
Dose changes 5 increases Every 4 weeks

Ozempic vs. Zepbound Indications

Ozempic

Ozempic is FDA-approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It also lowers cardiovascular risk in adults with type 2 diabetes and known heart disease, and slows kidney disease progression in adults with type 2 diabetes and chronic kidney disease. Using it for weight loss is off-label, not an FDA-approved use.

  • Blood sugar control in type 2 diabetes, with diet and exercise

  • Lowers risk of heart attack, stroke, and death in T2D with heart disease

  • Slows kidney damage progression in T2D with chronic kidney disease

  • Off-label: prescribed for weight loss in people without diabetes

  • Not approved for type 1 diabetes or chronic weight management

Zepbound

Zepbound is FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition, combined with diet and exercise. It also holds a separate approval for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not approved to treat type 2 diabetes; that use belongs to its sister drug, Mounjaro.

  • Chronic weight management in adults with obesity

  • Chronic weight management in overweight adults with a related condition

  • Moderate-to-severe obstructive sleep apnea in adults with obesity

  • Used together with a reduced-calorie diet and exercise

  • Not approved for type 2 diabetes (that's Mounjaro)

Ozempic vs. Zepbound Pros and Cons

Ozempic

Ozempic's clinical profile centers on type 2 diabetes control, with added FDA backing for cardiovascular and kidney protection. Insurers generally cover it readily for diabetes, but coverage for off-label weight loss use is inconsistent and often denied.

Pros

  • FDA-approved to lower cardiovascular risk in type 2 diabetics with heart disease

  • FDA-approved to slow chronic kidney disease progression in type 2 diabetes

  • Long-standing safety record, on the market since 2017

  • Broadly covered by insurance for its approved diabetes indications

Cons

  • Not FDA-approved for weight loss, so that use is off-label

  • Targets only the GLP-1 receptor, generally producing less weight loss in trials than dual-target drugs

  • Insurance often denies coverage when prescribed off-label for weight loss

  • Maximum dose (2 mg) offers less titration flexibility than Zepbound's six strengths

Zepbound

Zepbound's clinical profile centers on weight loss, with an added FDA approval for obstructive sleep apnea. Its on-label status for weight management makes insurance coverage for that use more consistent than off-label prescribing of similar drugs.

Pros

  • FDA-approved specifically for chronic weight management, not an off-label use

  • Also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity

  • Dual GIP/GLP-1 mechanism associated with greater average weight loss in trials

  • Six dose strengths (2.5 mg to 15 mg) allow finer titration steps

Cons

  • Not FDA-approved to treat type 2 diabetes; that use belongs to its sister drug Mounjaro

  • No FDA approval for cardiovascular risk reduction, unlike Ozempic

  • No FDA approval for slowing kidney disease progression, unlike Ozempic

  • Shorter track record, first approved in 2022 versus Ozempic's 2017 approval

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.